Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
4-Year Grace Period Was Good News, but More Should Be Done for Re-Pricing Exclusion: FPMAJ
The introduction of a four-year grace period for so-called “spillover” re-pricing in April marked a certain improvement, but more reforms need to be done for exclusion criteria for such price cuts, the Federation of Pharmaceutical Manufacturers’ Associations of Japan (FPMAJ)…
To read the full story
Related Article
- It’s Time to Revise G1 Withdrawal Scheme, Rule Likely to Be Applied to Only a Few Products: FPMAJ
June 14, 2022
- FPMAJ Urges More Precise Handling of CEA Price Tweaks for Products with “Cost Increase” Profile
June 13, 2022
- FPMAJ Pushes Minimal Product Scope for Off-Year Re-Pricing, No Cut in 2% Buffer Zone: Annual Report
June 13, 2022
ORGANIZATION
- FIRM Backs Growth Roadmap, Expects Better Investment Climate
July 10, 2026
- JPMA Sees Honebuto Shifting toward Industry Promotion, Still Against Off-Year Cuts
July 10, 2026
- Labor Group Urges Govt to Scrap FY2027 Off-Year Drug Price Cuts
July 7, 2026
- Japan’s Contract Rep Workforce Hits Record High in FY2025
July 6, 2026
- Japan’s Generic Use Rate Climbs to 89.7% in FY2025: JGA
July 6, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…